Lenacapavir Injection Gains Popularity in Western Cape with Over 3,600 Initiations

In a significant stride for HIV prevention, the lenacapavir injection is witnessing an impressive uptake in the Western Cape, with over 3,600 individuals having initiated the treatment as of August 23. The new injectable, administered every six months, is seen as a game-changer compared to the previous two-monthly cabotegravir injection, particularly among vulnerable young women.

At the bustling Philippi Village in Cape Town, 20-year-old Olwam Plaatjie shared her experience of switching to lenacapavir after three years on cabotegravir. Despite minor side effects like small nodules at the injection sites, she expresses satisfaction with the new regimen. Plaatjie highlights the importance of proactive health measures, especially in a community where many young women face the risk of HIV.

According to Foster Mohale from the national Department of Health, as of late August, 3,641 lenacapavir initiations have occurred across 22 clinics in the Western Cape, contributing to a national total of 47,934. However, the rollout is currently limited to 360 health facilities across six provinces, with Gauteng leading the way.

Hilary Goeiman, Director of Service Priorities Coordination for the Western Cape's Department of Health and Wellness, noted that the program is strategically targeting adolescent girls and young women, who are at higher risk for HIV. The success of clinics like the Nolungile Community Health Centre in Khayelitsha exemplifies effective implementation of the lenacapavir program.

Of particular note, Goeiman reported that 258 pregnant women have also begun the lenacapavir treatment at these clinics since June, reflecting the program's inclusive approach to HIV prevention.

The Desmond Tutu Health Foundation is conducting a study in collaboration with the Western Cape Department of Health to evaluate the implementation of lenacapavir among a cohort of young individuals aged 15 to 35. Elzette Rousseau, a social behavioral expert at the foundation, aims to enroll at least 1,500 participants over 18 months to assess ongoing use and effectiveness.

Participants like Lutho Windvoel voiced their enthusiasm for the injection's convenience, stating it alleviates the daily burden of taking oral PrEP. Windvoel and others acknowledged that while some men are apprehensive about needles, the six-month duration of protection encourages them to overcome their fears.

In discussions about men’s hesitance to engage in HIV prevention, Sive Mphambaniso from the Desmond Tutu Health Foundation remarked on the challenges but also the progress being made. He noted that many men previously preferred oral medication but are now opting for injections due to their extended efficacy.

The lenacapavir injection consists of two 1.5ml doses, which can be administered in various locations such as the abdomen or thigh. Recipients have reported minor bumps at the injection sites, but these typically subside without causing discomfort. Nurse Zimasa Zwide explained that these nodules often develop in slimmer individuals and assured that most patients do not experience pain.

While some users have reported discomfort initially, measures such as using ice packs before injections are being used at certain facilities to enhance the experience. The administration kit includes the necessary syringes and tablets that aid in the absorption of lenacapavir.

Source: www.dailymaverick.co.za